DTC Report: DTC Gets Smart
DTC Report: 10 Riskiest DTC Ads Ever
Rare Diseases: Orphans in Danger
Therapeutic Focus 2014: Respiratory
Headliner: Pharma's type "A" exec—and mentor
Non-Personal Promotion: A New Era in E-Sampling
Read the 2014 Game Changers digital edition
Skill Sets Live: Content Marketing for Healthcare
Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also reaped blockbuster sales for Gilead.
The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.
Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.
The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.
What brand managers need to know to achieve data security maturity
Express Scripts warned of building an anti-Sovaldi coalition. If payers are unwilling to pay for such drugs, or band against their makers, where does pharma go from here?
Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."
But demand for Enbrel and Aranesp slipped.
The candidate would be the first to put oxycodone and morphine in one capsule.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
The new MM&M e-book, "Oncology Marketing," is designed to serve as a companion for those in the business of communicating cancer products to all three stakeholders. It's packed with analysis, advice, insights and commentary to help navigate the terrain. Click here to access it.